Shots:

• Prestige Biopharma announces that EMA has accepted & validated MAA for its Tuznue- a biosimilar to Herceptin (trastuzumab) on May 23- 2019
• Prestige’s Tuznue will be in competition with Celltrion’s Herzuma- Amgen’s Kanjinti- Merck Sharp & Dohme’s Ontruzant & Pfizer’s Trazimera in the European market- dominated by Roche’s Herceptin
• Tuznue (HD201) is currently evaluated in P-I/P-III global studies and has received CHMP’s positive opinion for marketing authorization from the EMA. Additionally- Prestige has 8 biosimilar & biologics in its portfolio which are at different development stages

Ref: Prestige BioPharma | Image: Prestige Biopharma